# The interplay between the extracellular matrix and extracellular vesicle-associated microRNAs

**Authors:** Yunjie Wu, Nicolo Toldo, Muller Fabbri

PMC · DOI: 10.1186/s12964-025-02630-0 · 2026-01-07

## TL;DR

This paper explores how the extracellular matrix and microRNA-carrying vesicles interact to influence tissue health and disease.

## Contribution

It highlights the bidirectional regulation between the ECM and EV-miRNAs and their roles in disease progression.

## Key findings

- The ECM influences EV biogenesis, miRNA sorting, and transport.
- EV-miRNAs modulate ECM composition and remodeling.
- Aberrant ECM-EV-miRNA signaling contributes to cancer progression and tissue fibrosis.

## Abstract

The extracellular matrix (ECM) is a dynamic and bioactive structure that provides both physical scaffolding and regulatory cues essential for tissue homeostasis, development, and disease. In parallel, extracellular vesicles (EVs) and their associated microRNAs (miRNAs) have emerged as critical mediators of intercellular communication, influencing diverse physiological and pathological processes. Increasing evidence highlights a reciprocal interplay between the ECM and EV-miRNAs: the ECM regulates EV biogenesis, miRNA sorting, transport, and uptake, while EV-miRNAs modulate ECM composition, remodeling, and mechanobiology. This bidirectional crosstalk has profound implications for tissue repair, fibrosis, and cancer progression, where aberrant ECM-EV-miRNA signaling contributes to matrix stiffening, immune modulation, angiogenesis, and metastasis. Recent findings demonstrate that ECM mechanics and biochemical factors dictate EV cargo profiles and delivery efficiency, whereas EV-miRNAs regulate the expression of ECM proteins and remodeling enzymes, thereby shaping the microenvironment. Despite significant advances, the molecular mechanisms underlying ECM-governed miRNA trafficking and EV-miRNA-driven ECM remodeling remain incompletely understood. A deeper mechanistic understanding of ECM-EV-miRNA interactions will not only shed light on fundamental aspects of microenvironmental signaling but also open new avenues for the development of ECM- and EV-based therapies for regenerative medicine and cancer treatment.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** Npnt (nephronectin) [NCBI Gene 114249] {aka 1110009H02Rik, Nctn, POEM}, ARF6 (ARF GTPase 6) [NCBI Gene 382], MIR141 (microRNA 141) [NCBI Gene 406933] {aka MIRN141, mir-141}, DICER1 (dicer 1, ribonuclease III) [NCBI Gene 23405] {aka DCR1, Dicer, Dicer1e, GLOW, HERNA, K12H4.8-LIKE}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, MIR29A (microRNA 29a) [NCBI Gene 407021] {aka MIRN29, MIRN29A, hsa-mir-29, hsa-mir-29a, miRNA29A, mir-29a}, LAMB2 (laminin subunit beta 2) [NCBI Gene 3913] {aka LAMS, NPHS5, PIERS}, MIR27A (microRNA 27a) [NCBI Gene 407018] {aka MIR27, MIRN27A, mir-27a}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, TRAM2 (translocation associated membrane protein 2) [NCBI Gene 9697], MIR200A (microRNA 200a) [NCBI Gene 406983] {aka MIRN200A, mir-200a}, TGFBI (transforming growth factor beta induced) [NCBI Gene 7045] {aka BIGH3, CDB1, CDG2, CDGG1, CSD, CSD1}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, ANXA2 (annexin A2) [NCBI Gene 302] {aka ANX2, ANX2L4, CAL1H, HEL-S-270, LIP2, LPC2}, PDCD4 (programmed cell death 4) [NCBI Gene 27250] {aka H731}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, IGF2BP1 (insulin like growth factor 2 mRNA binding protein 1) [NCBI Gene 10642] {aka CRD-BP, CRDBP, IMP-1, IMP1, VICKZ1, ZBP1}, Fn1 (fibronectin 1) [NCBI Gene 14268] {aka E330027I09, Fn, Fn-1}, TGFBR2 (transforming growth factor beta receptor 2) [NCBI Gene 7048] {aka AAT3, FAA3, LDS1B, LDS2, LDS2B, MFS2}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, CAV1 (caveolin 1) [NCBI Gene 857] {aka BSCL3, CGL3, LCCNS, MSTP085, PPH3, VIP21}, MIR223 (microRNA 223) [NCBI Gene 407008] {aka MIRN223, miRNA223, mir-223}, FMR1 (fragile X messenger ribonucleoprotein 1) [NCBI Gene 2332] {aka FMRP, FRAXA, POF, POF1}, Fndc3a (fibronectin type III domain containing 3A) [NCBI Gene 319448] {aka 1700094E19Rik, D14Ertd453e, F730017H24Rik, Fndc3, sys}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, MIR15A (microRNA 15a) [NCBI Gene 406948] {aka MIRN15A, hsa-mir-15a, miRNA15A, mir-15a}, MIR3174 (microRNA 3174) [NCBI Gene 100422841], COL4A1 (collagen type IV alpha 1 chain) [NCBI Gene 1282] {aka BSVD, BSVD1, COL4A1s, PADMAL, RATOR}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, PDCD6IP (programmed cell death 6 interacting protein) [NCBI Gene 10015] {aka AIP1, ALIX, DRIP4, HP95, MCPH29}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, MIR155 (microRNA 155) [NCBI Gene 406947] {aka MIRN155, miRNA155, mir-155}, HPSE (heparanase) [NCBI Gene 10855] {aka HPA, HPA1, HPR1, HPSE1, HSE1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, Mir378a (microRNA 378a) [NCBI Gene 723889] {aka Mir378, Mirn378, mmu-mir-378, mmu-mir-378a}, SMPD3 (sphingomyelin phosphodiesterase 3) [NCBI Gene 55512] {aka NSMASE2}, Myocd (myocardin) [NCBI Gene 214384] {aka BSAC2A, Srfcp}, HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1) [NCBI Gene 3181] {aka HNRNPA2, HNRNPB1, HNRPA2, HNRPA2B1, HNRPB1, IBMPFD2}, MIR432 (microRNA 432) [NCBI Gene 574451] {aka MIRN432, hsa-mir-432, mir-432}, E2F2 (E2F transcription factor 2) [NCBI Gene 1870] {aka E2F-2}, LOX (lysyl oxidase) [NCBI Gene 4015] {aka AAT10}, ACAN (aggrecan) [NCBI Gene 176] {aka AGC1, AGCAN, CSPG1, CSPGCP, MSK16, SEDK}, MIR107 (microRNA 107) [NCBI Gene 406901] {aka MIRN107, miR-107}, CTTN (cortactin) [NCBI Gene 2017] {aka EMS1}, TLR8 (toll like receptor 8) [NCBI Gene 51311] {aka CD288, IMD98, TLR-8, hTLR8}, RAB27A (RAB27A, member RAS oncogene family) [NCBI Gene 5873] {aka GS2, HsT18676, RAB27, RAM}, TIMP2 (TIMP metallopeptidase inhibitor 2) [NCBI Gene 7077] {aka CSC-21K, DDC8}, MIR17 (microRNA 17) [NCBI Gene 406952] {aka MIR17-5p, MIR91, MIRN17, MIRN91, hsa-mir-17, miR-17}, GJA1 (gap junction protein alpha 1) [NCBI Gene 2697] {aka AVSD3, CMDR, CX43, EKVP, EKVP3, GJAL}, ELAVL1 (ELAV like RNA binding protein 1) [NCBI Gene 1994] {aka ELAV1, HUR, Hua, MelG}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, Mir23a (microRNA 23a) [NCBI Gene 387216] {aka Mirn23a, mir-23a, mmu-mir-23a}, MMP14 (matrix metallopeptidase 14) [NCBI Gene 4323] {aka MMP-14, MMP-X1, MT-MMP, MT-MMP 1, MT1-MMP, MT1MMP}, MDM2 (MDM2 proto-oncogene) [NCBI Gene 4193] {aka ACTFS, HDMX, LSKB, hdm2}, RASSF5 (Ras association domain family member 5) [NCBI Gene 83593] {aka Maxp1, NORE1, NORE1A, NORE1B, RAPL}, SAFB (scaffold attachment factor B) [NCBI Gene 6294] {aka HAP, HET, SAB-B1, SAF-B, SAF-B1, SAFB1}, IL17RA (interleukin 17 receptor A) [NCBI Gene 23765] {aka CANDF5, CD217, CDw217, IL-17RA, IL17R, IMD51}, AGO2 (argonaute RISC catalytic component 2) [NCBI Gene 27161] {aka CASC7, EIF2C2, LESKRES, LINC00980, PPD, Q10}
- **Diseases:** inflammation (MESH:D007249), metabolic diseases (MESH:D008659), central nervous system (CNS) disorders (MESH:D002493), breast cancer (MESH:D001943), tumorigenesis (MESH:D063646), arthritis (MESH:D001168), colorectal cancer (MESH:D015179), pain (MESH:D010146), Hypoxia (MESH:D000860), cardiovascular diseases (MESH:D002318), metastasis (MESH:D009362), muscle (MESH:D019042), insulin resistance (MESH:D007333), prostate cancer (MESH:D011471), diabetes mellitus (MESH:D003920), hernias (MESH:D006547), cartilage-destructive diseases (MESH:D002357), Tumor (MESH:D009369), HCC (MESH:D006528), fibrosis (MESH:D005355), hypoxic (MESH:D002534), rheumatoid arthritis (MESH:D001172), tumorigenic (MESH:D002471), lung cancer (MESH:D008175), melanoma (MESH:D008545), pulmonary fibrosis (MESH:D011658), degenerative diseases (MESH:D019636), multiple myeloma (MESH:D009101), infarction (MESH:D007238), papillary thyroid cancer (MESH:D000077273), neuroblastoma (MESH:D009447), liver (MESH:D017093), pancreatic cancer (MESH:D010190), ESCC (MESH:D000077277), osteoarthritis (MESH:D010003), intervertebral disc degeneration (MESH:D055959), keloid (MESH:D007627), beta-cell injury (MESH:D007340)
- **Chemicals:** glycans (MESH:D011134), hyaluronic acid (MESH:D006820), Cholesterol (MESH:D002784), bortezomib (MESH:D000069286), heparan sulfate (MESH:D006497), ceramide (MESH:D002518), GelMA (-), GAG (MESH:D006025), pantoprazole (MESH:D000077402), silica (MESH:D012822), glucose (MESH:D005947), Lipid (MESH:D008055), histamine (MESH:D006632), calcium (MESH:D002118), heparin (MESH:D006493)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12870969/full.md

---
Source: https://tomesphere.com/paper/PMC12870969